REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • February 28th, 2023 • Allarity Therapeutics, Inc. • Pharmaceutical preparations
Contract Type FiledFebruary 28th, 2023 Company IndustryThis Registration Rights Agreement (this “Agreement”) is made and entered into as of February 28, 2023, between Allarity Therapeutics, Inc., a Delaware corporation (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • February 28th, 2023 • Allarity Therapeutics, Inc. • Pharmaceutical preparations • New York
Contract Type FiledFebruary 28th, 2023 Company Industry JurisdictionThis Securities Purchase Agreement (this “Agreement”) is dated as of February 28, 2023, between Allarity Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
LIMITED WAIVER AGREEMENTLimited Waiver Agreement • February 28th, 2023 • Allarity Therapeutics, Inc. • Pharmaceutical preparations
Contract Type FiledFebruary 28th, 2023 Company IndustryThis Limited Waiver Agreement ( the “Waiver”), dated and to be effective as of February 28, 2023, is made by and between Allarity Therapeutics, Inc., a Delaware corporation (the “Company”), and 3i, L.P., a Delaware limited partnership (the “Investor”). The Company and the Investor may also each be referred to herein, individually as a “Party” and collectively as the “Parties.” Unless otherwise defined in this Waiver, capitalized terms have the same meaning as defined in the Company’s Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock (the “Series A COD”), the Securities Purchase Agreement by and between the Parties, dated May 20, 2021 (as amended, the “SPA”), the common stock purchase warrants, dated May 20, 2021, and issued to the Investor (the “Warrants” and together with the Series A COD and SPA, the “PIPE Documents”), and the Secured Note Purchase Agreement, dated November 22, 2022, by and between the Parties (the “Note Purchas